Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ENFN Stock Summary
Top 10 Correlated ETFs
ENFN
In the News

The 3 Most Undervalued Under-$10 Stocks to Buy in September 2023
Finding undervalued stocks is one of the key strategies for successful investing. Undervalued stocks are those that trade below their intrinsic value, meaning that the market has not fully recognized their “true potential.

Enfusion, Inc. (ENFN) Q2 2023 Earnings Call Transcript
Enfusion, Inc. (NYSE:ENFN ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Iggy Njoku - Head, IR Oleg Movchan - CEO Brad Herring - CFO Conference Call Participants Kevin McVeigh - Credit Suisse Parker Lane - Stifel James Faucette - Morgan Stanley Callie Valenti - Goldman Sachs Dylan Becker - William Blair Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Enfusion Second Quarter 2023 Earnings Conference Call.

Here's What Key Metrics Tell Us About Enfusion, Inc. (ENFN) Q2 Earnings
While the top- and bottom-line numbers for Enfusion, Inc. (ENFN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Enfusion, Inc. (ENFN) Q2 Earnings and Revenues Lag Estimates
Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.04 per share a year ago.

Enfusion Announces Date of Second Quarter 2023 Results
NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of cloud-native software-as-a-service (SaaS) solutions for investment managers, today announced it will release its second quarter 2023 financial results before the U.S. financial markets open on Tuesday, August 8, 2023. Management will host a conference call and webcast that same morning at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results. To access this call, dial (888) 330-2502. The.

META vs. ENFN: Which Stock Should Value Investors Buy Now?
Investors with an interest in Internet - Software stocks have likely encountered both Meta Platforms (META) and Enfusion, Inc. (ENFN). But which of these two stocks presents investors with the better value opportunity right now?

Enfusion: H2 2023 Growth Acceleration Is The Catalyst To Share Price Rerating
I believe Enfusion is undervalued and poised for recovery, despite short-term financial challenges due to macro turmoil. The company's ability to sign new hedge funds and its international growth opportunities are positive indicators for future growth acceleration. ENFN valuation compared to expected revenue growth shows potential for closing the gap with competitors like FactSet.

Enfusion, Inc. (ENFN) Q1 2023 Earnings Call Transcript
Enfusion, Inc. (NYSE:ENFN ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Ignatius Njoku - Head, IR Oleg Movchan - CEO Brad Herring - CFO Conference Call Participants Dylan Becker - William Blair James Faucette - Morgan Stanley J. Parker Lane - Stifel Nicolaus Koji Ikeda - Bank of America Operator Good morning, ladies and gentlemen.

Bull Of The Day: Enfusion (ENFN)
This stock has some good historical and projected topline growth.

Enfusion, Inc. (ENFN) Flat As Market Sinks: What You Should Know
In the latest trading session, Enfusion, Inc. (ENFN) closed at $8.56, marking no change from the previous day.
ENFN Financial details
ENFN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
Revenue per share | 0.92 | 1.24 | 1.35 | 1.76 | |
Net income per share | 0.2 | 0.06 | -3.4 | -0.16 | |
Operating cash flow per share | 0.19 | 0.03 | 0 | 0.17 | |
Free cash flow per share | 0.12 | -0.05 | -0.1 | 0.07 | |
Cash per share | 0.09 | 0.22 | 0.78 | 0.73 | |
Book value per share | -1.84 | -3.65 | 0.67 | 0.76 | |
Tangible book value per share | -1.84 | -3.65 | 1.17 | 1.21 | |
Share holders equity per share | -1.84 | -3.65 | 0.67 | 0.76 | |
Interest debt per share | 0.44 | 1.56 | 0.06 | 0.09 | |
Market cap | 1.27B | 1.27B | 1.74B | 825.75M | |
Enterprise value | 1.29B | 1.35B | 1.67B | 770.19M | |
P/E ratio | 100.28 | 312.53 | -6.16 | -62.26 | |
Price to sales ratio | 21.5 | 15.95 | 15.57 | 5.49 | |
POCF ratio | 103.13 | 762.26 | -5.47K | 58.33 | |
PFCF ratio | 161.12 | -372.95 | -208.71 | 132.65 | |
P/B Ratio | -10.77 | -5.43 | 31.45 | 12.7 | |
PTB ratio | -10.77 | -5.43 | 31.45 | 12.7 | |
EV to sales | 21.87 | 17.01 | 14.99 | 5.12 | |
Enterprise value over EBITDA | 85.93 | 160.27 | -6.13 | -137.05 | |
EV to operating cash flow | 104.9 | 813.09 | -5.27K | 54.41 | |
EV to free cash flow | 163.89 | -397.82 | -200.98 | 123.73 | |
Earnings yield | 0.01 | 0 | -0.16 | -0.02 | |
Free cash flow yield | 0.01 | 0 | 0 | 0.01 | |
Debt to equity | -0.23 | -0.42 | 0 | 0.11 | |
Debt to assets | 1.19 | 2.52 | 0 | 0.06 | |
Net debt to EBITDA | 1.45 | 10.02 | 0.24 | 9.89 | |
Current ratio | 2 | 2.71 | 11.06 | 5.57 | |
Interest coverage | 19.16 | 3.65 | -60.05 | -28.97 | |
Income quality | 0.97 | 0.41 | 0 | -1.07 | |
Dividend Yield | 0.01 | 0 | 0 | 0 | |
Payout ratio | 0.87 | 1.14 | -0.01 | 0 | |
Sales general and administrative to revenue | 0.28 | 0.45 | 1.35 | 0.46 | |
Research and developement to revenue | 0.07 | 0.08 | 1.37 | 0.11 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.36 | -3.04 | 25.2 | -0.56 | |
Capex to revenue | -0.08 | -0.06 | -0.07 | -0.05 | |
Capex to depreciation | -3.83 | -2.21 | -2.02 | -1.25 | |
Stock based compensation to revenue | 0 | 0 | 2.59 | 0.17 | |
Graham number | 2.86 | 2.28 | 7.14 | 1.63 | |
ROIC | -0.15 | -0.04 | -5 | -0.16 | |
Return on tangible assets | 0.55 | 0.1 | -2.66 | -0.11 | |
Graham Net | -2 | -3.9 | 0.84 | 0.76 | |
Working capital | 8.1M | 18.26M | 81.57M | 79.43M | |
Tangible asset value | -117.88M | -233.56M | 97.44M | 103.44M | |
Net current asset value | -124.91M | -243.75M | 81.03M | 76.47M | |
Invested capital | -0.23 | -0.42 | 0 | 0.11 | |
Average receivables | 0 | 10.58M | 15.2M | 22.04M | |
Average payables | 0 | 463.5K | 1.51M | 2.11M | |
Average inventory | 0 | 0 | 0 | 3.05M | |
Days sales outstanding | 55.5 | 55.88 | 59.55 | 62.77 | |
Days payables outstanding | 9.53 | 8.27 | 28.98 | 13.06 | |
Days of inventory on hand | 0 | 0 | 0 | 47.31 | |
Receivables turnover | 6.58 | 6.53 | 6.13 | 5.82 | |
Payables turnover | 38.29 | 44.13 | 12.6 | 27.95 | |
Inventory turnover | 0 | 0 | 0 | 7.71 | |
ROE | -0.11 | -0.02 | -5.1 | -0.2 | |
Capex per share | -0.07 | -0.08 | -0.1 | -0.09 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0.43 | 0.46 | 0.47 | 0.46 | 0.48 | |
Net income per share | -0.05 | 0.03 | 0.01 | 0.05 | 0.01 | |
Operating cash flow per share | 0.03 | 0.09 | 0.09 | 0.01 | 0.07 | |
Free cash flow per share | 0.01 | 0.08 | 0.07 | -0.02 | 0.04 | |
Cash per share | 0.67 | 0.75 | 0.73 | 0.61 | 0.31 | |
Book value per share | 0.7 | 0.72 | 0.76 | 0.72 | 0.54 | |
Tangible book value per share | 1.18 | 1.21 | 1.21 | 1.12 | 0.82 | |
Share holders equity per share | 0.7 | 0.72 | 0.76 | 0.72 | 0.54 | |
Interest debt per share | 0 | 0 | 0.09 | 0.17 | 0.15 | |
Market cap | 863.57M | 1.05B | 825.75M | 933.06M | 990.88M | |
Enterprise value | 807.01M | 987.28M | 770.19M | 892.12M | 975.93M | |
P/E ratio | -52.34 | 101.12 | 261.98 | 49.69 | 393.83 | |
Price to sales ratio | 23.63 | 26.84 | 20.38 | 22.77 | 23.19 | |
POCF ratio | 298.81 | 134 | 109.79 | 1.01K | 164.65 | |
PFCF ratio | 1.08K | 151.85 | 142.99 | -573.84 | 260.83 | |
P/B Ratio | 14.6 | 17.19 | 12.7 | 14.65 | 20.59 | |
PTB ratio | 14.6 | 17.19 | 12.7 | 14.65 | 20.59 | |
EV to sales | 22.09 | 25.22 | 19.01 | 21.77 | 22.84 | |
Enterprise value over EBITDA | -206.66 | 215.19 | 247.65 | 136.26 | 215.53 | |
EV to operating cash flow | 279.24 | 125.9 | 102.41 | 965.5 | 162.17 | |
EV to free cash flow | 1.01K | 142.67 | 133.37 | -548.66 | 256.89 | |
Earnings yield | 0 | 0 | 0 | 0.01 | 0 | |
Free cash flow yield | 0 | 0.01 | 0.01 | 0 | 0 | |
Debt to equity | 0 | 0 | 0.11 | 0.21 | 0.27 | |
Debt to assets | 0 | 0 | 0.06 | 0.11 | 0.14 | |
Net debt to EBITDA | 14.48 | -13.85 | -17.86 | -6.25 | -3.3 | |
Current ratio | 9.17 | 8.01 | 5.57 | 6.32 | 4.33 | |
Interest coverage | -3.91K | 735.25 | 3.24 | 3.5 | 0 | |
Income quality | -0.7 | 3.02 | 9.54 | 0.2 | 6.03 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.5 | 0.33 | 0.37 | 0.35 | 0.38 | |
Research and developement to revenue | 0.1 | 0.1 | 0.12 | 0.11 | 0.1 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.72 | -0.12 | -0.23 | -2.76 | -0.37 | |
Capex to revenue | -0.06 | -0.02 | -0.04 | -0.06 | -0.05 | |
Capex to depreciation | -1.3 | -0.54 | -1.03 | -1.37 | -1.07 | |
Stock based compensation to revenue | 0.21 | 0.01 | 0.1 | -0.03 | 0.06 | |
Graham number | 0.88 | 0.7 | 0.4 | 0.92 | 0.3 | |
ROIC | -0.07 | 0.04 | 0.01 | 0.05 | 0.03 | |
Return on tangible assets | -0.04 | 0.02 | 0.01 | 0.04 | 0.01 | |
Graham Net | 0.82 | 0.87 | 0.76 | 0.6 | 0.31 | |
Working capital | 80.41M | 84.04M | 79.43M | 72.94M | 45.87M | |
Tangible asset value | 99.81M | 103.17M | 103.44M | 99.15M | 72.24M | |
Net current asset value | 79.93M | 83.6M | 76.47M | 64.3M | 37.82M | |
Invested capital | 0 | 0 | 0.11 | 0.21 | 0.27 | |
Average receivables | 26.09M | 28.88M | 27.42M | 25.11M | 24.76M | |
Average payables | 1.03M | 1.03M | 1.44M | 1.49M | 1.08M | |
Average inventory | 4.55M | 3.12M | 4.36M | 5.85M | 5.28M | |
Days sales outstanding | 70.86 | 66.65 | 57.43 | 53.5 | 53.03 | |
Days payables outstanding | 7.29 | 8.91 | 11.41 | 8.73 | 5.5 | |
Days of inventory on hand | 30.15 | 19.58 | 41.32 | 37.89 | 31.46 | |
Receivables turnover | 1.27 | 1.35 | 1.57 | 1.68 | 1.7 | |
Payables turnover | 12.34 | 10.1 | 7.89 | 10.31 | 16.37 | |
Inventory turnover | 2.98 | 4.6 | 2.18 | 2.38 | 2.86 | |
ROE | -0.07 | 0.04 | 0.01 | 0.07 | 0.01 | |
Capex per share | -0.02 | -0.01 | -0.02 | -0.03 | -0.03 |
ENFN Frequently Asked Questions
What is Enfusion, Inc. stock symbol ?
Enfusion, Inc. is a US stock , located in Chicago of Il and trading under the symbol ENFN
What is Enfusion, Inc. stock quote today ?
Enfusion, Inc. stock price is $8.825 today.
Is Enfusion, Inc. stock public?
Yes, Enfusion, Inc. is a publicly traded company.